Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 5/20 | 0.33 |
| ▸ | PIK3CA | P42336 | 5/20 | 0.33 |
| ▸ | GRM4 | Q14833 | 3/20 | 0.32 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.32 |
| ▸ | CNR2 | P34972 | 2/20 | 0.31 |
| ▸ | HASPIN | Q8TF76 | 1/20 | 0.30 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20641876 | 0.76 | GPR119 (0.44) | — | |
| SCHEMBL20641975 | 0.74 | TBK1 (0.41) | — | |
| SCHEMBL20642083 | 0.73 | MAPK1 (0.36) | LRRK2PIK3CAMAPK1 | |
| SCHEMBL20642084 | 0.73 | MAPK1 (0.36) | LRRK2PIK3CAMAPK1 | |
| SCHEMBL25207890 | 0.72 | SYK (0.43) | LRRK2PDE4BCNR2 | |
| SCHEMBL25520600 | 0.72 | CNR2 (0.41) | LRRK2CNR2 | |
| SCHEMBL25224829 | 0.71 | — | — | |
| SCHEMBL15565804 | 0.68 | MEN1 (0.38) | HASPIN | |
| SCHEMBL29897656 | 0.68 | HASPIN (0.41) | HASPIN | |
| SCHEMBL16094976 | 0.65 | ALOX5AP (0.37) | LRRK2PIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200291018-A1 | TAM KINASE INHIBITORS | SYROS PHARMACEUTICALS, INC. (US) | 2020-09-17 | — | — | US | disclosed |
| EP-3652174-A1 | TAM KINASE INHIBITORS | Syros Pharmaceuticals, Inc. (US) | 2020-05-20 | — | — | EP | disclosed |
| WO-2019014513-A1 | TAM KINASE INHIBITORS | SYROS PHARMACEUTICALS, INC. (US) | 2019-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200291018-A1 | TAM KINASE INHIBITORS | MAP3K1, PIK3CA, MAP3K5 | LRRK2 715/4885PIK3CA 2/4885GRM4 1866/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.